{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Brexpiprazole", "query": { "intervention": "Brexpiprazole" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 57, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Brexpiprazole&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T10:35:17.599Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01944969", "title": "Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Brexpiprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lundbeck A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2013-10", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2018-10-17", "last_synced_at": "2026-09-02T10:35:17.599Z", "location_count": 1, "location_summary": "Orlando, Florida", "locations": [ { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01944969" }, { "nct_id": "NCT02400346", "title": "Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depression Disorder" ], "interventions": [ { "name": "Adjunct brexpiprazole", "type": "DRUG" }, { "name": "ADT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lundbeck A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 132, "start_date": "2015-03", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2017-08-10", "last_synced_at": "2026-09-02T10:35:17.599Z", "location_count": 13, "location_summary": "Arcadia, California • Miami, Florida • Orlando, Florida + 9 more", "locations": [ { "city": "Arcadia", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Smyrna", "state": "Georgia" }, { "city": "O'Fallon", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02400346" }, { "nct_id": "NCT03557931", "title": "A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "ASP4345", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "risperidone", "type": "DRUG" }, { "name": "quetiapine", "type": "DRUG" }, { "name": "olanzapine", "type": "DRUG" }, { "name": "ziprasidone", "type": "DRUG" }, { "name": "aripiprazole", "type": "DRUG" }, { "name": "brexpiprazole", "type": "DRUG" }, { "name": "paliperidone", "type": "DRUG" }, { "name": "lurasidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 233, "start_date": "2018-07-13", "completion_date": "2019-10-21", "has_results": true, "last_update_posted_date": "2024-11-12", "last_synced_at": "2026-09-02T10:35:17.599Z", "location_count": 27, "location_summary": "Cerritos, California • Garden Grove, California • Lemon Grove, California + 19 more", "locations": [ { "city": "Cerritos", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Lemon Grove", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Pico Rivera", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03557931" }, { "nct_id": "NCT01670279", "title": "Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Brexpiprazole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "70 Years to 85 Years" }, "enrollment_count": 18, "start_date": "2012-07", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2016-02-04", "last_synced_at": "2026-09-02T10:35:17.599Z", "location_count": 4, "location_summary": "Kissimmee, Florida • Miami, Florida • St Louis, Missouri + 1 more", "locations": [ { "city": "Kissimmee", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01670279" }, { "nct_id": "NCT01942785", "title": "Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depressive Disorder", "Irritability" ], "interventions": [ { "name": "Brexpiprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lundbeck A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 55, "start_date": "2013-10", "completion_date": null, "has_results": true, "last_update_posted_date": "2016-03-15", "last_synced_at": "2026-09-02T10:35:17.599Z", "location_count": 15, "location_summary": "Tucson, Arizona • Glendale, California • Oakland, California + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Glendale", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01942785" }, { "nct_id": "NCT02013531", "title": "Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depressive Disorder", "Anxiety" ], "interventions": [ { "name": "Brexpiprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 37, "start_date": "2013-11", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2016-03-29", "last_synced_at": "2026-09-02T10:35:17.599Z", "location_count": 21, "location_summary": "Tuscon, Arizona • Garden Grove, California • Oceanside, California + 18 more", "locations": [ { "city": "Tuscon", "state": "Arizona" }, { "city": "Garden Grove", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Temecula", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02013531" }, { "nct_id": "NCT01854944", "title": "PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Brexpiprazole 1mg to 4mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 12, "start_date": "2013-09", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2016-02-04", "last_synced_at": "2026-09-02T10:35:17.599Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01854944" }, { "nct_id": "NCT04002700", "title": "A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Stroke" ], "interventions": [ { "name": "Haloperidol", "type": "DRUG" }, { "name": "Typical Antipsychotics", "type": "DRUG" }, { "name": "Atypical Antipsychotics", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1234412, "start_date": "2019-05-06", "completion_date": "2019-05-31", "has_results": false, "last_update_posted_date": "2025-06-25", "last_synced_at": "2026-09-02T10:35:17.599Z", "location_count": 1, "location_summary": "Titusville, New Jersey", "locations": [ { "city": "Titusville", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04002700" }, { "nct_id": "NCT04258839", "title": "Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Irritability Associated With Autism Spectrum Disorder" ], "interventions": [ { "name": "Brexpiprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "5 Years to 17 Years" }, "enrollment_count": 95, "start_date": "2020-01-23", "completion_date": "2023-03-16", "has_results": true, "last_update_posted_date": "2024-05-30", "last_synced_at": "2026-09-02T10:35:17.599Z", "location_count": 28, "location_summary": "Dothan, Alabama • Phoenix, Arizona • San Francisco, California + 24 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04258839" }, { "nct_id": "NCT01862640", "title": "A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Agitation Associated With", "Alzheimer's Disease", "Alzheimer's Type", "Mental Disorder", "Nervous System Diseases" ], "interventions": [ { "name": "Brexpiprazole, OPC-34712", "type": "DRUG" }, { "name": "Placebo Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "55 Years to 90 Years" }, "enrollment_count": 433, "start_date": "2013-07-11", "completion_date": "2017-03-15", "has_results": true, "last_update_posted_date": "2020-12-31", "last_synced_at": "2026-09-02T10:35:17.599Z", "location_count": 37, "location_summary": "Tuscaloosa, Alabama • Phoenix, Arizona • Bellflower, California + 25 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bellflower", "state": "California" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Downey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01862640" } ] }